Key Points
CCO.AX stock surges 50% to A$0.003 in pre-market trading today
Revenue growth accelerates 88.5% but company remains unprofitable with negative cash flow
Debt-to-equity ratio of 22.94 and persistent losses raise financial stability concerns
Technical oversold conditions and strong money flow suggest short-term trading momentum
The Calmer Co International Limited (CCO.AX) is making waves in pre-market trading today, with CCO.AX stock climbing 50% to reach A$0.003 per share on the ASX. This sharp intraday surge reflects renewed trading activity in the kava wellness company, which operates across Australia, New Zealand, Fiji, and the United States. The stock opened at A$0.002 and has already touched its daily high of A$0.003, with trading volume reaching 168,958 shares—significantly above the average daily volume of 2.49 million. Investors are watching closely as CCO.AX stock continues its volatile trajectory in the pre-market session.
Understanding The Calmer Co’s Market Position
The Calmer Co International Limited, formerly known as Fiji Kava Limited, rebranded in April 2023 to reflect its broader wellness focus. The company produces and sells noble kava extract capsules and powder mixes under the Fiji Kava and Taki Mai brand names, targeting the growing medicinal wellness market. Based in West End, Queensland, the company operates within the Consumer Defensive sector and Packaged Foods industry.
With a market capitalisation of A$6.75 million and 2.7 billion shares outstanding, CCO.AX stock remains a micro-cap play. The company’s 50-day price average sits at A$0.00343, while the 200-day average is A$0.0034225. Year-to-date performance shows a decline of 37.5%, though today’s pre-market surge offers a glimmer of momentum for holders.
Financial Health and Key Metrics
Meyka AI rates CCO.AX with a grade of B, suggesting a HOLD recommendation. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.
The company faces significant financial headwinds. Revenue per share stands at A$0.0027, while net income per share is negative at A$-0.0011. The price-to-sales ratio of 0.83 appears attractive, but profitability metrics tell a concerning story. Operating cash flow per share is negative at A$-0.00097, and free cash flow per share is A$-0.00098. The debt-to-equity ratio of 22.94 signals heavy leverage, while the current ratio of 1.85 provides modest liquidity cushion. Track CCO.AX on Meyka for real-time updates on these metrics.
Market Sentiment and Trading Activity
Today’s pre-market surge reflects renewed interest in CCO.AX stock, though the broader trend remains challenging. The stock’s year-high of A$0.005 and year-low of A$0.002 frame a narrow trading range. Relative volume today stands at 1.75x average, indicating above-normal participation.
Technical indicators show mixed signals. The RSI of 45.89 suggests neutral momentum, while the Stochastic %K and %D both sit at 16.67, indicating oversold conditions that may have triggered today’s bounce. The Money Flow Index of 65.79 suggests strong buying pressure in recent sessions. However, the negative MACD histogram and declining moving average envelope slope of -1.74 warn of underlying weakness. The Rate of Change at 25% reflects today’s sharp intraday gain.
Operational Performance and Growth Outlook
The Calmer Co reported mixed financial growth metrics for the fiscal year ending June 30, 2025. Revenue growth accelerated 88.5%, while gross profit grew 69.8%, demonstrating strong top-line expansion. However, operating income declined 16.5%, and net income fell 7.1%, revealing margin compression challenges.
Earnings per share grew 51.5%, though this reflects significant share dilution with weighted average shares increasing 117.5%. Operating cash flow declined 110.5%, and free cash flow fell 120.4%, raising concerns about cash generation. The company’s earnings announcement is scheduled for August 28, 2026. With negative ROE of -3.23 and negative ROA of -0.61, profitability remains elusive despite revenue growth.
Final Thoughts
Calmer Co’s 50% pre-market surge reflects trading momentum, not fundamental strength. Strong 88.5% revenue growth in kava products is offset by persistent losses, negative cash flow, and heavy debt. The B grade rating suggests a HOLD stance. With a 97.7% five-year decline and volatile history, traders may capitalize on the rally, but long-term investors should wait for August earnings and stronger financial metrics before investing.
FAQs
The surge reflects renewed trading activity and technical oversold conditions (Stochastic 16.67), with strong money flow index of 65.79 indicating buying pressure. This represents short-term momentum rather than fundamental company improvement.
CCO produces and sells noble kava extract capsules and powder mixes under Fiji Kava and Taki Mai brands across Australia, New Zealand, Fiji, and the United States, targeting the medicinal wellness market.
No. The company reports negative earnings per share of A$-0.0011, negative operating cash flow, ROE of -3.23%, and ROA of -0.61%, indicating ongoing losses despite 88.5% revenue growth.
Key risks include high debt-to-equity ratio of 22.94, negative cash flow, persistent losses, extreme volatility (97.7% five-year decline), and micro-cap status with A$6.75 million market cap creating liquidity risk.
The earnings announcement is scheduled for August 28, 2026, providing updated financial metrics and management guidance on the path to profitability and cash flow improvement.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)